During a median follow-up time of 6.4 years (minimum: 5.1; 25th percentile: 6.0; 75th percentile: 6.6; maximum: 7.7), out of 1773 nondiabetic participants with MR-proANP measurements, 119 developed T2D, and out of 960 nondiabetic participants with copeptin, CT-proET-1 and MR-proADM measurements, 72 developed T2D. This evidence concerns the gene NPPA and type 2 diabetes mellitus.